Healthy Skepticism Library item: 11368
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: Journal Article
Ratain MJ, Cohen EE.
The value meal: how to save $1,700 per month or more on lapatinib.
J Clin Oncol 2007 Aug 10; 25:(23):3397-8
http://jco.ascopubs.org/cgi/content/full/25/23/3397
Abstract:
Drug labels (ie, package inserts) must be approved by national regulatory agencies (eg, US Food and Drug Administration), and are the product of a negotiation between the drug’s sponsor and the regulators. Labels are intended to provide important information for prescribers, pharmacists, and patients regarding the drug’s indication(s) and toxicities, but also include information regarding the drug’s pharmacokinetics, which may not be of interest to most prescribers.
However, the label for lapatinib1 (approved by the US Food and Drug Administration on March 13, 2007) includes a number of pharmacokinetic details of high interest to both prescribers and patients. A most notable finding-also presented at the 2007 meeting of the American Society for Clinical Pharmacology and Therapeutics2-is that the bioavailability of lapatinib is greatly increased by food, especially a high-fat meal…
Keywords:
MeSH Terms:
Administration, Oral
Clinical Trials
Drug Administration Schedule
Drug Interactions
Drug Labeling
Drug Packaging
Eating*
Economics, Medical
Humans
Quinazolines/economics*
Quinazolines/pharmacology
Time Factors
Substances:
Quinazolines
lapatinib
Notes:
Free full text
